Free tool
FAERS Monitor: Elrexfio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761345 or its brand name (Elrexfio, Elranatamab). Reports on generic versions are filed under their own applications.
Reports
1,158
Serious
989
85% of reports
Hospitalization
347
Death reported
279
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome207
- death115
- malignant neoplasm progression87
- pyrexia82
- immune effector cell-associated neurotoxicity syndrome60
- pneumonia59
- fatigue58
- cytomegalovirus infection reactivation57
- off label use49
- plasma cell myeloma45
- rash45
- infection44
- diarrhoea40
- neutropenia40
- decreased appetite33
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 5 |
| 2024 | 190 |
| 2025 | 556 |
| 2026 | 407 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,001 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus infection reactivationSignal | 57 | 237.4 | 184.0 | 13,016 |
| cytokine release syndromeSignal | 207 | 189.4 | 167.3 | 38,239 |
| immune effector cell-associated neurotoxicity syndromeSignal | 60 | 185.9 | 145.1 | 10,741 |
| plasma cell myelomaSignal | 45 | 21.0 | 15.7 | 837 |
| malignant neoplasm progressionSignal | 87 | 15.4 | 12.6 | 1,165 |
| infectionSignal | 44 | 5.5 | 4.1 | 160 |
| neutropeniaSignal | 40 | 5.3 | 3.9 | 138 |
| pyrexiaSignal | 82 | 4.3 | 3.5 | 208 |
| pneumoniaSignal | 59 | 3.3 | 2.6 | 94 |
| decreased appetiteSignal | 33 | 2.6 | 1.8 | 31 |
| deathSignal | 115 | 2.4 | 2.0 | 99 |
| rash | 45 | 1.9 | 1.4 | 18 |
| fatigue | 58 | 1.4 | 1.1 | 5 |
| diarrhoea | 40 | 1.1 | 0.8 | 0 |
| off label use | 49 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.